Adoptive cell-mediated immunotherapy with interleukin-2 (IL-2) for relapsing lymphoblastic crisis following mismatched unrelated bone marrow transplantation in a chronic myelogenous leukemia patient.

Abstract

A 21-year-old woman with chronic myelogenous leukemia (CML) relapsed into lymphoblastic crisis with new chromosomal translocations, 4 months following mismatched unrelated allogeneic bone marrow transplantation (BMT). Adoptive cell-mediated immunotherapy with mismatched unrelated donor lymphocytes followed by 3 days of in vivo interleukin-2 (IL-2) resulted in complete remission including disappearance of the Philadelphia chromosome as determined by cytogenetic analysis and the bcr/abl translocation detected by PCR. Lymphoblastic crisis following mismatched, unrelated BMT is relatively rare. Moreover lymphoblastic malignancies usually respond less favorably to cell-mediated immunotherapy. This case is the first reported CML lymphoblastic crisis following mismatched unrelated BMT that responded to cell-mediated immunotherapy and IL-2. Some possible mechanisms and new therapeutic directions are discussed.

• Authors: G Varadi, A Ackerstein, S Ben-Neriah, A Nagler
• Journal: Bone marrow transplantation (Bone Marrow Transplant) Vol. 21 Issue 1 Pg. 93-6 (Jan 1998) ISSN: 0268-3369 [Print] England
• PMID: 9486502 (Publication Type: Case Reports, Journal Article)

Chemical References

• Interleukin-2

Topics

• Adult
• Blast Crisis (therapy)
• Bone Marrow Transplantation (adverse effects, immunology)
• Female
• Graft vs Host Disease (etiology)
• Humans
• Immunotherapy, Adoptive
• Interleukin-2 (therapeutic use)
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (pathology, therapy)